Common light chain mAbs targeting tumor-associated antigens are assembled into bispecific antibodies (BsAb) with a low mismatch rate and ideal physiochemical properties. This approach allows for simultaneous targeting of multiple tumor-driven proteins, offering a potential solution to drug resistance. Moreover, recognition of cells co-expressing both targets enhances tumor specificity while minimizing off-target toxicity.
RenMab™ mice contain the entire human immunoglobulin variable domain, which streamlines discovery and eliminates the need for humanization. Our RenLite® model contains a fixed common light chain that eliminates chain mispairing during bispecific antibody development. Immunized RenMice undergo in vivo selection and affinity maturation to generate quality antibody hits.
Biocytogen provides hundreds of genetically modified off-the-shelf BioMice for basic and preclinical research. Our large collection of humanized immune-checkpoint, humanized cytokine/cytokine receptor, humanized TAA mice, and immunodeficient mice, which have been published in hundred of studies, facilitate in vivo efficacy assessments of novel anti-human immunotherapies.
We’re proud to share that we’ll be exhibiting at the CBA-GP Biomedical Science Symposium 2025! Scheduled for February 8th in Philadelphia, this prestigious event offers ...
We’re excited to share that we’ll be exhibiting at BIO Partnering @JPM Week 2025! Happening January 13th to 16th in San Francisco, California, this renowned ...
We’re thrilled to announce our participation as an exhibitor at Biotech Showcase 2025! Taking place from January 13th to 15th in San Francisco, California, this ...
We’re thrilled to announce our participation as an exhibitor at AET (Antibody Engineering & Therapeutics) US 2024! From December 15th to 18th in San Diego, ...
We’re thrilled to announce our participation as an exhibitor at BioFIT 2024! From December 3rd to 4th in Lille, France, this prestigious event will bring ...
Powered by cutting-edge gene editing technologies and a state-of-the-art animal facility, Biocytogen offers solutions for preclinical antibody drug discovery and efficacy validation. Our CRO & vivarium sites in Boston and China have enabled global partnerships with numerous academic and industrial clients to accelerate basic and preclinical research.
Powered by cutting-edge gene editing technologies and a state-of-the-art animal facility, Biocytogen offers solutions for preclinical antibody drug discovery and efficacy validation. Our CRO & vivarium sites in Boston and China have enabled global partnerships with numerous academic and industrial clients to accelerate basic and preclinical research.
Founded in 2009, our proprietary, efficient genetic engineering technologies have made us a global leader in animal and cell model generation. Development of our advanced chromosome engineering technology and high-throughput antibody discovery platform further expanded our capabilities for therapeutic antibody discovery using our fully human antibody mice.
With the largest catalog of humanized models available and an experienced in vivo pharmacology team, we have completed over 1,300 drug evaluation projects. Our fast turnaround times and dedication to superior customer service have set us apart.
Whether you need gene editing or pharmacology services, our cutting-edge platforms provide fast and reliable solutions.